| mRNA |
tanespimycin:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.0043 |
0.9 |
| mRNA |
CCT007093 |
GDSC1000 |
pan-cancer |
AAC |
-0.0037 |
0.9 |
| mRNA |
BRD-K71935468 |
CTRPv2 |
pan-cancer |
AAC |
0.0041 |
0.9 |
| mRNA |
SB-525334 |
CTRPv2 |
pan-cancer |
AAC |
0.0039 |
0.9 |
| mRNA |
PF-573228 |
CTRPv2 |
pan-cancer |
AAC |
0.0036 |
0.9 |
| mRNA |
decitabine:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.0032 |
0.9 |
| mRNA |
MLN2238 |
CTRPv2 |
pan-cancer |
AAC |
-0.0035 |
0.9 |
| mRNA |
docetaxel:tanespimycin (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.0032 |
0.9 |
| mRNA |
CAL-101 |
GDSC1000 |
pan-cancer |
AAC |
-0.003 |
0.9 |
| mRNA |
PL-DI |
CTRPv2 |
pan-cancer |
AAC |
0.003 |
0.9 |